Covid-19 vaccine: PM Modi seeks Australia's support for temporary IP waiver

The development comes in the wake of the US backing temporarily suspending intellectual property protection for Covid-19 vaccines

Modi
Prime Minister Narendra Modi. Photo: PIB India
Shreya Nandi New Delhi
2 min read Last Updated : May 07 2021 | 11:45 PM IST
Prime Minister Narendra Modi on Friday sought Australia's support to seek a temporary waiver from certain provisions of the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement. The waiver is aimed at ensuring that more countries get equitable access to vaccines and medicines for Covid-19.
 
"Spoke with my friend Scott Morrison MP to thank him for Australia’s solidarity and support for India’s fight against the pandemic. We agreed on the importance of ensuring affordable and equitable access to vaccines and medicines, and discussed possible initiatives in this regard," Modi said in a tweet.
 
The development comes in the wake of the US backing temporarily suspending intellectual property protection for Covid-19 vaccines. The US will also actively participate in the World Trade Organization’s (WTO’s) negotiations to make that happen.
 
Soon after the announcement of support from the US, New Zealand and the European Union also expressed their willingness to back the waiver. However, some countries, including Australia, continue to oppose the proposal of India and South Africa at the WTO for a temporary waiver under TRIPS.
 
In a telephonic conversation, Modi and the Australian PM Scott Morrison MP agreed on the need to ensure affordable and equitable access to vaccines and medicines for containing Covid-19 globally. "The leaders took note of the progress made in the India-Australia Comprehensive Strategic Partnership since the Virtual Summit held on 4 June 2020 and discussed ways to further strengthen cooperation and foster people-to-people ties," an official statement said.
 
 
 


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineNarendra Modi

Next Story